Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeogenFRA:NG2 +0.24%68 PB Ratio is 1.03 as of Jul. 14, 2026, which is 79% below its 10-year median of 4.92. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.72 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Neogen ranks better than 79.57% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-14), Neogen's share price is €8.416. Neogen's Book Value per Share for the quarter that ended in Feb. 2026 was €8.17. Hence, Neogen's PB Ratio of today is 1.03.
The historical rank and industry rank for Neogen's PB Ratio or its related term are showing as below:
FRA:NG2'
s PB Ratio Range Over the Past 10 Years
Min: 0.36 Med: 4.92 Max: 8.63
Current: 1
During the past 13 years, Neogen's highest PB Ratio was 8.63. The lowest was 0.36. And the median was 4.92.
FRA:NG2's PB Ratio is ranked better than 79.57% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs FRA:NG2: 1.00
During the past 12 months, Neogen's average Book Value Per Share Growth Rate was -21.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Neogen was 28.40% per year. The lowest was -10.60% per year. And the median was 14.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Neogen PB Ratio Related Terms
Neogen PB Ratio Historical Data
* Premium members only.
The historical data trend for Neogen's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Neogen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's PB Ratio distribution charts can be found below:
* The bar in red indicates where Neogen's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Neogen's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Neogen (FRA:NG2) has a PB Ratio of 1.03 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neogen and its competitors. This is 79% below median its historical median of 4.92. Over the past decade, Neogen's PB Ratio has ranged from 0.36 to 8.63. According to the industry distribution chart, Neogen ranks #161 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 20.4%.
Is Neogen's PB Ratio too high?
Neogen's current PB Ratio of 1.03 is 79% below median its 10-year median of 4.92. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 8.63. The Medical Devices & Instruments industry median PB Ratio is 2.05. Neogen's value of 1.03 is 49.8% below this industry median. Based on the distribution chart, Neogen ranks #161 out of 788 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's PB Ratio compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #161 out of 788 companies for PB Ratio. This places Neogen in the top 20% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Neogen's value of 1.03 is 49.8% below this benchmark. Historically, Neogen's own PB Ratio has ranged from 0.36 to 8.63 over the past decade. While the company's 10-year median is 4.92 vs. the industry median of 2.05, Neogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current PB Ratio of 1.03 is 49.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current PB Ratio is 1.03, which is 79% below median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.72, compared to a current price of €8.42 — trading 21.5% below its estimated fair value. The current PB Ratio is 1.03, which is 79% below median its 10-year median of 4.92 and 49.8% below the Medical Devices & Instruments industry median of 2.05. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Neogen (FRA:NG2), the current PB Ratio is 1.03 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €8.42 is trading 21.5% below its estimated GF Value™ of €10.72.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
PB Ratio: 1.03 (79% below median its 10-year median of 4.92)
GF Value™: €10.72 vs. price of €8.42 (21.5% below fair value)
Industry Position: 49.8% below the Medical Devices & Instruments median (#161 of 788)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
